Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-4 (Cancelled)

5 (Previously Presented). A vector comprising a DNA sequence according to claim 44.

6 (Original). A vector according to claim 5 capable of being expressed in a eukaryotic host cell

7 (Original). A vector according to claim 5 capable of being expressed in a prokaryotic host cell.

8 (Original). Transformed eukaryotic or prokaryotic host cells containing a vector according to claim 5.

9-10 (Canceled)

11 (Previously Presented). A method for producing a polypeptide which potentiates cell death, which comprises growing a transformed host cell according to claim ~~8~~—55under conditions suitable for the expression of an expression product, effecting post-translational modification of said expression product, as necessary, for obtaining said polypeptide, and isolating said expressed polypeptide.

12-22 (Canceled)

23 (Previously Presented). A composition comprising a pharmaceutically acceptable excipient and a recombinant

animal virus vector comprising a DNA sequence according to claim 44.

24 (Currently Amended). A composition comprising a pharmaceutically acceptable excipient and an oligonucleotide molecule consisting of an antisense sequence of at least part of ~~an mRNA sequence corresponding to~~ a DNA sequence ~~according to claim 44~~ encoding the polypeptide of SEQ ID NO:1, said part of the DNA sequence being of sufficient length to effectively block the expression of said polypeptide upon use.

25-43 (Canceled).

44 (Previously Presented). An isolated DNA sequence consisting essentially of a sequence encoding a polypeptide which potentiates cell death, said polypeptide consisting of:

(a) a sequence comprising SEQ ID NO:1;

(b) a sequence comprising an analog of (a) having no more than ten changes in the amino acid sequence of (a), each said change being a substitution, deletion or insertion of a single amino acid, which analog potentiates cell death; or

(c) a fragment of the sequence of SEQ ID NO:1, which fragment potentiates cell death.

45 (Previously Presented). A DNA sequence in accordance with claim 44 consisting essentially of a sequence encoding a polypeptide of a sequence comprising SEQ ID NO:1.

46 (Previously Presented). A DNA sequence in accordance with claim 44, consisting essentially of a sequence encoding a polypeptide consisting of the sequence of (b).

47 (Previously Presented). A DNA sequence in accordance with claim 44, consisting essentially of a sequence encoding a polypeptide consisting of the sequence of (c).

48 (Previously Presented). A DNA sequence in accordance with claim 44, consisting essentially of SEQ ID NO:2 or a portion thereof encoding a polypeptide which potentiates cell death.

49-50 (Canceled).

51 (Currently Amended). An isolated oligonucleotide molecule consisting of an antisense sequence of at least a part of ~~an mRNA sequence corresponding to~~ a DNA sequence ~~according to claim 44~~encoding the polypeptide of SEQ ID NO:1, said part of the DNA sequence being of sufficient length to effectively block the expression of said polypeptide upon use.

52-53 (Cancelled)

54 (Previously Presented). An isolated DNA sequence in accordance with claim 44 wherein the entire DNA sequence is a coding sequence encoding said polypeptide.

55 (New). Isolated transformed eukaryotic or prokaryotic host cells containing a vector according to claim 5.

56 (New). A composition comprising a pharmaceutically acceptable excipient and an oligonucleotide molecule consisting of an antisense sequence of at least part of a mRNA sequence encoding the polypeptide of SEQ ID NO:1, said part of the mRNA sequence being of sufficient length to effectively block the expression of said polypeptide upon use.

57 (New). An isolated oligonucleotide molecule consisting of an antisense sequence of at least a part of a mRNA sequence encoding the polypeptide of SEQ ID NO:1, said part of the mRNA sequence being of sufficient length to effectively block the expression of said polypeptide upon use.

In the Sequence Listing

Please enter the attached Sequence Listing, numbered as pages 1-5.

Please substitute the attached Sequence Listing section for the Sequence Listing previously of record.